Giuseppina Calareso
University of Milan
CancerInternal medicineRadiologySurgeryMagnetic resonance imagingOncologyStage (cooking)Clinical endpointChemotherapyGerm cell tumorsDurvalumabDacomitinibRadiomicsPembrolizumabSalvage therapyLocally advancedSingle groupIn patientOpen labelPhases of clinical researchCancer researchMedicine
Publications 120
#1Valentina D. A. Corino (Polytechnic University of Milan)H-Index: 15
#2Marco Bologna (Polytechnic University of Milan)H-Index: 6
Last. Paolo Bossi (University of Brescia)H-Index: 39
view all 20 authors...
Baseline clinical prognostic factors for recurrent and/or metastatic (RM) head and neck squamous cell carcinoma (HNSCC) treated with immunotherapy are lacking. CT-based radiomics may provide additional prognostic information. A total of 85 patients with RM-HNSCC were enrolled for this study. For each tumor, radiomic features were extracted from the segmentation of the largest tumor mass. A pipeline including different feature selection steps was used to train a radiomic signature prognostic for ...
#1Salvatore AlfieriH-Index: 17
Last. Lisa Licitra (University of Milan)H-Index: 70
view all 29 authors...
To identify and validate baseline magnetic resonance imaging (b-MRI) radiomic features (RFs) as predictors of disease outcomes in effectively cured head and neck squamous cell carcinoma (HNSCC) pat...
#1Laura Marandino (University of Milan)H-Index: 9
#2Daniele Raggi (University of Milan)H-Index: 20
Last. Andrea Necchi (UniSR: Vita-Salute San Raffaele University)H-Index: 12
view all 11 authors...
Abstract Background : Durvalumab and cabozantinib have shown single-agent activity in patients with metastatic urothelial carcinoma (UC). ARCADIA is a phase 2 study evaluating their combination in patients with platinum-treated, advanced UC (NCT03824691). Herein we report the results of the planned interim safety analysis and the preliminary activity. Methods : Patients with an ECOG performance status 0-1, UC and non-UC histology, failure of a maximum of 2 regimens received cabozantinib 40 mg da...
#1Lisa SeratiH-Index: 1
#2Carlo MorosiH-Index: 37
Last. Alfonso MarchianòH-Index: 33
view all 11 authors...
Abstract Background Percutaneous core needle biopsy (PCNB) has become an accepted method to collect tumour tissue samples given its safety, minimal invasiveness, high accuracy and cost-effectiveness. Procedure It is a single centre, retrospective evaluation of 213 ultrasound (US) or computed tomography (CT) guided PCNBs of paediatric solid tumours performed from 2005 to 2017. Safety, diagnostic yield, accuracy, and efficacy assessments of the PCNB procedure were performed. Univariate logistic mo...
1 CitationsSource
#1Paolo MancaH-Index: 6
#2Salvatore CoralloH-Index: 12
Last. Filippo Pietrantonio (University of Milan)H-Index: 30
view all 27 authors...
Abstract Background In patients with metastatic colorectal cancer (mCRC) receiving highly active first-line combination treatments, early tumor shrinkage (ETS) and depth of response (DoR) are associated with survival, but their influence on outcomes during maintenance therapy is unknown. The Valentino study showed inferior PFS in 229 RAS wild-type mCRC patients randomized to panitumumab plus FOLFOX followed by maintenance with panitumumab vs. panitumumab + 5-FU/LV. Patients and methods After bli...
2 CitationsSource
Clinical data of ri-SGCs patients treated between 2015 and 2019 at a tertiary cancer center and a national hadron therapy facility were reviewed. Latent time (LT) from first RT to ri-SGCs diagnosis, overall (OS), and disease-free survival (DFS) were assessed. Thirteen patients developed 14 ri-SGCs (one patient had 2 synchronous ri-SCGs), after a median LT of 23 years (range 16–34). Parotid was the primary site in 8 cases (57%) and salivary duct carcinoma was the most frequent histotype (29%). Ni...
Introduction Both DURVA and CABO, an inhibitor of MET, AXL, and VEGFR, have shown single-agent activity in pts with UC. ARCADIA is a phase 2 study evaluating the combination of CABO with DURVA in pts with advanced UC or non-UC histology (NCT03824691). Herein we report the results of the interim safety analysis and the preliminary activity. Methods Pts receive CABO 40 mg daily, orally, and are administered DURVA 1500 mg, intravenously, q28 days, until disease progression (PD, by RECIST 1.1) or on...
#1E. OrlandiH-Index: 3
#2Giuseppina CalaresoH-Index: 14
Last. Marco BolognaH-Index: 6
view all 19 authors...
#2G. InfanteH-Index: 1
Last. E. OrlandiH-Index: 3
view all 15 authors...
#1Simon KeekH-Index: 5
Last. P. LambinH-Index: 9
view all 19 authors...